• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Bio-Path Holdings, Inc.

    Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Reports Third Quarter 2024 Financial Results
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces Publication in Biomedicines
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Reports Second Quarter 2024 Financial Results
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Provides Clinical Update and Expansion Plans
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Reports First Quarter 2024 Financial Results
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Expands Global Patent Portfolio
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Provides 2024 Clinical and Operational Update
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Reports Full Year 2023 Financial Results
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Tickers BPTH
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.